Hims & Hers is transforming telehealth with personalized medications, rapid subscription growth, and strong financials, ...

Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...

It’s been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling.

Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no ...

Hims & Hers Health (NYSE: HIMS) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a ...

The Short discusses a 15% drop in Hims & Hers stock following an FDA announcement ending the shortage of Eli Lilly's weight ...

Craig Hettenbach, an analyst from Morgan Stanley, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated ...

Hims & Hers Health (NYSE:HIMS) is rewriting the telehealth playbook while its competitors scramble. With a 200% YTD surge, the company's diversified approachcombining virtual consultations ...

In terms of liquidity and interest, the mean open interest for Hims & Hers Health options trades today is 3348.53 with a ...

Hers provides medications for weight loss, hair loss, mental health, sexual health, and more. Here’s the lowdown on how it works and what it costs. Share on Pinterest Hers, a part of the Hims ...